Skip to main content

Table 3 Relationship of MYCN status to the clinicobiological characteristics of BM metastatic NB (n = 81)

From: MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma

Characteristics Total n (%) MYCN-amplification n (%) MYCN-normal n (%) P values*
Gender
 Male 51 (63.0) 7 (53.8) 44 (64.7) 0.536
 Female 30 (37.0) 6 (46.2) 24 (35.3)  
Age (months)
 <12 3 (3.7) 0 (0) 3 (4.4) 0.038
 12–18 4 (4.9) 2 (15.4) 2 (2.9)  
 18–24 11 (13.6) 4 (30.8) 7 (10.3)  
 >24 63 (77.8) 7 (53.8) 56 (82.4)  
Treatment group
 LR 3 (3.7) 0 (0) 3 (4.4) 0.999
 IR 3 (3.7) 0 (0) 3 (4.4)  
 HR 75 (92.6) 13 (100) 62 (91.2)  
LDH (IU/L)
 <1500 55 (67.9) 3 (23.1) 52 (76.5) <0.001
 ≥1500 26 (31.1) 10 (76.9) 16 (23.5)  
NSE (UG/L)
 <100 10 (12.3) 0 (0) 10 (14.7) 0.352
 ≥100 71 (87.7) 13 (100) 58 (85.3)  
Primary site
 Abdomen 73 (90.1) 12 (92.3) 61 (89.7) 0.999
 Thorax 6 (7.4) 1 (7.7) 5 (7.4)  
 Others 2 (2.5) 0 (0) 2 (2.9)  
Event
 No event 54 (66.7) 5 (38.5) 49 (72.1) 0.026
 Event 27 (33.3) 8 (61.5) 19 (27.9)  
  1. NB neuroblastoma, BM bone marrow, LR low-risk, IR intermediate-risk, HR high-risk, LDH lactate dehydrogenase, NSE neuron specific enolase
  2. * Data were calculated by χ2 test